Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT ID: NCT02790632

Last Updated: 2018-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

374 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares EG-1962 to enteral nimodipine in the treatment of aneurysmal subarachnoid hemorrhage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage, Aneurysmal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EG-1962 Group

* 1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg
* Up to 21 days of placebo capsules/tablets

Group Type EXPERIMENTAL

EG-1962 (nimodipine microparticles)

Intervention Type DRUG

Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days

Enteral Nimodipine Group

* 1 dose of intraventricular normal saline
* Up to 21 days of oral nimodipine capsules/tablets

Group Type ACTIVE_COMPARATOR

Enteral Nimodipine

Intervention Type DRUG

Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EG-1962 (nimodipine microparticles)

Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days

Intervention Type DRUG

Enteral Nimodipine

Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ruptured saccular aneurysm confirmed by angiography and repaired by neurosurgical clipping or endovascular coiling
2. External ventricular drain in place
3. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 2-4 on the modified Fisher scale
4. WFNS grade 2, 3, or 4

Exclusion Criteria

1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm
2. Angiographic vasospasm prior to randomization
3. Evidence of a cerebral infarction with neurological deficit
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edge Therapeutics Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

R. Loch Macdonald, MD, PhD

Role: STUDY_CHAIR

Edge Therapeutics Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham Hospital

Birmingham, Alabama, United States

Site Status

Dignity Health; St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Site Status

University of California, San Francisco-Fresno

Fresno, California, United States

Site Status

Keck Hospital of USC

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

David Geffen School of Medicine at UCLA

Los Angeles, California, United States

Site Status

UCSF

San Francisco, California, United States

Site Status

Yale New Haven Hospital (YNHH)

New Haven, Connecticut, United States

Site Status

UF Health Shands Florida

Gainesville, Florida, United States

Site Status

Baptist Medical Center/Lyerly Neurosurgery

Jacksonville, Florida, United States

Site Status

Mayo Clinic Florida

Jacksonville, Florida, United States

Site Status

Tallahassee Neurological Clinic

Tallahassee, Florida, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

University of Illinois Hospital and Health Sciences System

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

University of Kentucky Medical Center

Lexington, Kentucky, United States

Site Status

University of Louisville Hospital

Louisville, Kentucky, United States

Site Status

University of Maryland Medical Systems

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Site Status

University of New Mexico Hospital

Albuquerque, New Mexico, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Lenox Hill Hospital

New York, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

UNC Hospitals Neuroscience Intensive Care Unit

Chapel Hill, North Carolina, United States

Site Status

Duke University Medical Pavilion

Durham, North Carolina, United States

Site Status

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

Providence St. Vincent Medical Center

Portland, Oregon, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Jefferson Hospital for Neuroscience

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston Air Force Base, South Carolina, United States

Site Status

Semmes Murphey Neurological Clinic

Memphis, Tennessee, United States

Site Status

Inova Fairfax Medical Campus

Falls Church, Virginia, United States

Site Status

VCU Medical Center

Richmond, Virginia, United States

Site Status

University of Washington, Harborview Medical Center

Seattle, Washington, United States

Site Status

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Nepean Hospital

Kingswood, New South Wales, Australia

Site Status

Royal Adelaide Hospital

Adelaide, , Australia

Site Status

Medizinische Universitat Innsbruck/Tirol Universitatsklinik fur Neurologie

Innsbruck, , Austria

Site Status

University of Alberta Hospital/Mackenzie Health Sciences Centre

Edmonton, Alberta, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Centre Hospitalier de l'Universite de Montreal (CHUM), Hopital Notre Dame

Montreal, Quebec, Canada

Site Status

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Faculty Hospital Hradec Kralove

Hradec Králové, Hradec Kralov, Czechia

Site Status

Faculty Hospital Brno

Brno, South Moravian, Czechia

Site Status

Faculty Hospital Ostrava

Ostrava, , Czechia

Site Status

Military University Hospital Prague

Prague, , Czechia

Site Status

Tampere University Hospital

Tampere, Pirkanmaa, Finland

Site Status

Helsinki University Hospital

Helsinki, , Finland

Site Status

Neuro Intensive Care Unit 102i; Campus Charite Mitte (CCM)

Berlin, , Germany

Site Status

Zentrum fur Neurochirurgie der Uniklinik Koln

Cologne, , Germany

Site Status

Universitatsklinikum Erlangen, Neurologische Klinik, Koptkliniken

Erlangen, , Germany

Site Status

Klinik für Neurochirurgie des Universitätsklinikum Essen

Essen, , Germany

Site Status

Klinik für Neurochirurgie, Zentrum der Neurologie und Neurochirurgie, Goethe-Universitätsklinikum Frankfurt am Main

Frankfurt am Main, , Germany

Site Status

Universitätsklinikum Hamburg Eppendorf, Klinik und Poliklinik für Neurochirurgie, Neues Klinikum

Hamburg, , Germany

Site Status

Neurochirurgische Klinik der Universität Heidelberg

Heidelberg, , Germany

Site Status

Klinik und Poliklinik für Neurochirurgie des Universitatsklinikum Leipzig

Leipzig, , Germany

Site Status

Neurochirurgische Klinik, Universitatsmedizin Mannheim, Universität Heidelberg

Mannheim, , Germany

Site Status

Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen

München, , Germany

Site Status

Neutochirurgische Klinik und Poliklinik des Universitatsklinikum Wurzburg

Würzburg, , Germany

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Prince of Wales Hospital

New Kowloon, , Hong Kong

Site Status

Rabin Medical Center

Petah Tikva, Petah-Tikva, Israel

Site Status

Rambam Health Care Center

Haifa, , Israel

Site Status

Hadassah Hebrew University Medical Center

Jerusalem, , Israel

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

National Neuroscience Institute

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Canada Czechia Finland Germany Hong Kong Israel New Zealand Singapore

References

Explore related publications, articles, or registry entries linked to this study.

Carlson AP, Hanggi D, Wong GK, Etminan N, Mayer SA, Aldrich F, Diringer MN, Schmutzhard E, Faleck HJ, Ng D, Saville BR, Bleck T, Grubb R Jr, Miller M, Suarez JI, Proskin HM, Macdonald RL; NEWTON Investigators. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage. Stroke. 2020 Apr;51(4):1142-1149. doi: 10.1161/STROKEAHA.119.027396. Epub 2020 Mar 6.

Reference Type DERIVED
PMID: 32138631 (View on PubMed)

Hanggi D, Etminan N, Mayer SA, Aldrich EF, Diringer MN, Schmutzhard E, Faleck HJ, Ng D, Saville BR, Macdonald RL; NEWTON Investigators. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)]. Neurocrit Care. 2019 Feb;30(1):88-97. doi: 10.1007/s12028-018-0575-z.

Reference Type DERIVED
PMID: 30014184 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EG-01-1962-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ticagrelor and Endothelial Function
NCT02261922 UNKNOWN PHASE4